drugset / Trial / NCT00098852
Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer
Phase 2
Unknown
25 enrolled
University of California, San Francisco
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Drugs such as rosiglitazone may make tumor cells more sensitive to radioactive iodine. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with locoregionally extensive or metastatic thyroid cancer.
Timeline
- Start
- 2004-10
- Primary completion
- 2010-06
- Completion
- —
Publications
- Results Kebebew E, Reiff E, Greenspan FS, et al.: Rosiglitazone treatment induces radioiodine uptake in some patients with radioiodine-negative thyroglobulin-positive differentiated thyroid cancer. [Abstract] The Endocrine Society's 87th Annual Meeting, 4-7 June 2005, San Diego, CA. A-P3-573, 2005. Also available online. Last accessed February 21, 2006.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rosiglitazone | Small molecule | — | Oral |